Taiho Pharmaceutical's press releases may contain information about prescription drugs including products currently under development, however information contained in the press releases are not intended to constitute promotion, advertisement, or medical advice.
Site search
2024
July 09, 2024
Taiho Pharmaceutical Exercises Option for an Exclusive License to Quemliclustat in Japan and Certain Territories in Asia（PDF：602.3 KB）
July 01, 2024
Taiho Pharmaceutical Establishes New Company, Arirge Co., Ltd., to Address Social Issues Related to Cancer
May 30, 2024
Otsuka Pharmaceutical and Taiho Pharmaceutical Commence Material Recycling of Waste PTP Used in Pharmaceutical Packaging（PDF：344.2 KB）
April 01, 2024
Corporate Venture Capital Firm Taiho Ventures Selected for AMED's Strengthening Program for Pharmaceutical Startup Ecosystem （PDF：239.7 KB）
March 13, 2024
Taiho Pharmaceutical Launches Solmack® Q-Arl D, Chewable Tablets for Diarrhea Caused by Overeating and Overdrinking that Can Be Taken Anywhere Without Water - A New Addition to the Solmack Product Line
March 01, 2024
Taiho Pharma Enters Exclusive License Agreement with Haihe Biopharma for Gumarontinib (SCC244), an Agent for Non-Small Cell Lung Cancer（PDF：354.6 KB）
February 07, 2024
Otsuka Group Selected for CDP Climate Change A List for a Second Consecutive Year（PDF：556.1 KB）
January 18, 2024
Taiho Pharmaceutical Reduces Employee Smoking Rate to 0.3%
January 09, 2024
Taiho Ventures Expands Investment Pool to $400 Million to Continue Quality Investments and Accelerate Open Innovation（PDF：262.2 KB）
News Releases
Select year from the Back Number
Back Number
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
